RecruitingPhase 1Phase 2NCT06800963

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

ResQ133A-NMIBC: Phase 1/2 Clinical Trial of Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Sponsor

ImmunityBio, Inc.

Enrollment

40 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

NMIBC

Summary

This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Intravesical Recombinant Mycobacterium (rMBCG) for people with nmibc. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALIntravesical Recombinant Mycobacterium (rMBCG)

19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)

Locations(9)

Arizona Clinical Trials

Chandler, Arizona, United States

Golden State Urology

Sacramento, California, United States

Emory University

Atlanta, Georgia, United States

Michigan Institute of Urology & Solaris Health

Troy, Michigan, United States

SUNY Upstate Medical University

Syracuse, New York, United States

MidLantic Urology

Cynwyd, Pennsylvania, United States

Conrad Pearson Clinic

Germantown, Tennessee, United States

Urology Associates, P.C.

Nashville, Tennessee, United States

Potamac Urology Center

Alexandria, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06800963

Related Trials

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

NCT07763197

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

NCT072078241 location

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

NCT074242872 locations

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT0548386817 locations

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

NCT069918681 location